Article
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Acta neuropathologica communications - 8 Aug 2016
Arita Hideyuki, Yamasaki Kai, Matsushita Yuko, Nakamura Taishi, Shimokawa Asanao, Takami Hirokazu, Tanaka Shota, Mukasa Akitake, Shirahata Mitsuaki, Shimizu Saki, Suzuki Kaori, Saito Kuniaki, Kobayashi Keiichi, Higuchi Fumi, Uzuka Takeo, Otani Ryohei, Tamura Kaoru, Sumita Kazutaka, Ohno Makoto, Miyakita Yasuji, Kagawa Naoki, Hashimoto Naoya, Hatae Ryusuke, Yoshimoto Koji, Shinojima Naoki, Nakamura Hideo, Kanemura Yonehiro, Okita Yoshiko, Kinoshita Manabu, Ishibashi Kenichi, Shofuda Tomoko, Kodama Yoshinori, Mori Kanji, Tomogane Yusuke, Fukai Junya, Fujita Koji, Terakawa Yuzo, Tsuyuguchi Naohiro, Moriuchi Shusuke, Nonaka Masahiro, Suzuki Hiroyoshi, Shibuya Makoto, Maehara Taketoshi, Saito Nobuhito, Nagane Motoo, Kawahara Nobutaka, Ueki Keisuke, Yoshimine Toshiki, Miyaoka Etsuo, Nishikawa Ryo, Komori Takashi, Narita Yoshitaka, Ichimura Koichi
Abstract excerpt
The prognostic impact of TERT mutations has been controversial in IDH-wild tumors, particularly in glioblastomas (GBM). The controversy may be attributable to presence of potential confounding factors such as MGMT methylation status or patients' treatment. This study aimed to evaluate the impact of TERT status on patient outcome in association with various factors in a large series of adult diffuse gliomas. We...
Read the complete abstract on PubMed